Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] D-2570 in Healthy Subjects
NCT07411742Phase 1Active, not recruiting
- Sponsor
- InventisBio
- Start
- Mar 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of D-2570, sponsored by InventisBio. Primary endpoints: Percentage of unchanged drug and its metabolites in plasma, urine and feces to the administered dose at 2 weeks, Total recovery in excrement at 2 weeks and 2 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
D-2570
Beyond the preview
Go deeper on NCT07411742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07411742.